ArticleScience (New York, N.Y.)2010
AIDS/HIV. A boost for HIV vaccine design.
Article in Science (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Ribosome Display Technology: Applications in Disease Diagnosis and Control.Antibodies (Basel, Switzerland) · 2020Review
- Induction of Fc-Mediated Effector Functions Against a Stabilized Inner Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region.Frontiers in immunology · 2019Article
- The expanding array of HIV broadly neutralizing antibodies.Retrovirology · 2018Review
- Recent advances in automated protein design and its future challenges.Expert opinion on drug discovery · 2018Review
- Circulating Plasmablasts from Chronically Human Immunodeficiency Virus-Infected Individuals Predominantly Produce Polyreactive/Autoreactive Antibodies.Frontiers in immunology · 2017Article
- Almighty antibodies? A new wave of antibody-based approaches aims to combat HIV.Nature medicine · 2015Article
- Receptor binding domain based HIV vaccines.BioMed research international · 2015Review
- Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin.ACS chemical biology · 2014Article
- Designer antigens for elicitation of broadly neutralizing antibodies against HIV.Clinical & translational immunology · 2014Article
- IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform.PLoS computational biology · 2014Article
- Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.BMC bioinformatics · 2014Article
- Review
- A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.PloS one · 2014Article
- An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Frontiers in immunology · 2014Review
- Article
- Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.Vaccines · 2013Review
- Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.Human vaccines & immunotherapeutics · 2013Article
- Immune activation and collateral damage in AIDS pathogenesis.Frontiers in immunology · 2013Review
- Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.Journal of virology · 2013Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20705840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.